Cullinan Therapeutics, Inc. (CGEM)
(Real Time Quote from BATS)
$7.88 USD
-0.20 (-2.48%)
Updated Aug 6, 2025 03:10 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Cullinan Therapeutics, Inc. has a market cap of $476.84M, which represents its share price of $8.08 multiplied by its outstanding shares number of 59.01M. As a small-cap company, CGEM's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CGEM 7.88 -0.20(-2.48%)
Will CGEM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGEM
Cullinan Therapeutics management to meet virtually with Clear Street
Cullinan Therapeutics management to meet virtually with Clear Street
Upcoming Virtual Meeting for Cogent Biosciences (CGEM) Investors
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at ...
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst